Abstract Background Disease modifying treatments (DMTs) for multiple sclerosis include
injectable drugs (iDMTs) like interferons (IFNs) or glatiramer acetate (GA), and newer agents
(nDMTs) in oral and intravenous forms. nDMTs are usually applied in escalation and less
frequently as initial treatment in pediatric-onset (POMS). Objective We intended to evaluate
the effect of nDMTs in comparison with iDMTs by retrospective examination of our patients
with POMS. Method Clinical records of POMS cases who received nDMTs either as …